Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Conference Highlights ASH
Conference Highlights ASH
Head-To-Head Comparison of Obinutuzumab Plus Chlorambucil versus Rituximab Plus Chlorambucil in Patients with Chronic Lymphocytic Leukemia and Coexisting Medical Conditions: Final Stage 2 Results of the CLL11 Trial
Play Video
Conference Highlights ASH
High Morbidity Burden Borne Years Later by Survivors of Transplant
Caroline Helwick
,
Caroline Helwick
Play Video
Conference Highlights ASH
Hospital Readmission After Stem-Cell Transplant Decreases Survival
Wayne Kuznar
Play Video
Conference Highlights ASH
Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed or Refractory CLL/SLL: Final Results of a Phase 1b Study
Play Video
Conference Highlights ASH
Ibrutinib in Combination with Rituximab is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High-Risk Chronic Lymphocytic Leukemia: New, Updated Results of a Phase 2 Trial in 40 Patients
Play Video
Conference Highlights ASH
Ibrutinib Overcomes Carfilzomib Resistance in Immunoproteasome-Deficient Mantle-Cell Lymphoma
Play Video
Conference Highlights ASH
Improving the Standard of Care
R. Donald Harvey, PharmD, FCCP, BCOP
Play Video
Conference Highlights ASH
JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis
Wayne Kuznar
Play Video
Conference Highlights ASH
Lenalidomide, Bendamustine, and Rituximab as First-Line Therapy for Patients >65 Years with Mantle-Cell Lymphoma: Preliminary Results from the Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase 1-2 Trial
Play Video
Conference Highlights ASH
More Transplants Made Possible Through Haploidentical Donors
Caroline Helwick
Play Video
1
2
3
4
Page 2 of 4
Results 11 - 20 of 35